A detailed history of Jpmorgan Chase & CO transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 374,373 shares of CPRX stock, worth $8.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
374,373
Previous 476,420 21.42%
Holding current value
$8.14 Million
Previous $7.59 Million 23.64%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$14.68 - $16.92 $1.5 Million - $1.73 Million
-102,047 Reduced 21.42%
374,373 $5.8 Million
Q1 2024

May 10, 2024

BUY
$13.18 - $17.11 $524,722 - $681,183
39,812 Added 9.12%
476,420 $7.59 Million
Q4 2023

Feb 12, 2024

BUY
$11.78 - $17.29 $19,919 - $29,237
1,691 Added 0.39%
436,608 $7.34 Million
Q3 2023

Nov 14, 2023

SELL
$11.69 - $15.02 $2.93 Million - $3.77 Million
-250,788 Reduced 36.57%
434,917 $5.08 Million
Q2 2023

Aug 11, 2023

SELL
$11.5 - $18.08 $754,952 - $1.19 Million
-65,648 Reduced 8.74%
685,705 $9.22 Million
Q1 2023

May 18, 2023

BUY
$14.34 - $21.05 $1.74 Million - $2.55 Million
121,214 Added 19.24%
751,353 $12.5 Million
Q1 2023

May 11, 2023

SELL
$14.34 - $21.05 $7.39 Million - $10.9 Million
-515,568 Reduced 45.0%
630,139 $10.4 Million
Q4 2022

Feb 13, 2023

SELL
$12.25 - $19.5 $2.26 Million - $3.59 Million
-184,285 Reduced 13.86%
1,145,707 $21.3 Million
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $1.44 Million - $3.17 Million
204,159 Added 18.13%
1,329,992 $17.1 Million
Q2 2022

Aug 11, 2022

SELL
$6.23 - $8.57 $381,811 - $525,221
-61,286 Reduced 5.16%
1,125,833 $7.89 Million
Q1 2022

May 11, 2022

SELL
$5.31 - $8.31 $56,631 - $88,626
-10,665 Reduced 0.89%
1,187,119 $9.84 Million
Q4 2021

Feb 10, 2022

BUY
$5.21 - $7.45 $122,007 - $174,464
23,418 Added 1.99%
1,197,784 $8.11 Million
Q3 2021

Nov 12, 2021

BUY
$4.85 - $6.04 $5.7 Million - $7.09 Million
1,174,366 New
1,174,366 $6.22 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.24B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.